Despite possessing one of the world's best clinical genomic databases, Memorial Sloan Kettering (MSK) recognized its limitations and partnered with Sophia Genetics. This highlights that collective intelligence from a federated network is essential, as even the most advanced single center cannot capture the full spectrum of patient diversity.

Regeneron identified the main constraint in drug discovery as a lack of validated targets, not a shortage of advanced therapeutic tools. Their genetics engine was created to explore the 90% of the human genome that was untargeted by existing or experimental medicines, aiming to solve this core problem.

Regeneron's focus on diverse populations is a core research strategy. Key discoveries, like the PCSK9 heart disease mutation, were only possible because they were significantly more common in African Americans. This proves that diverse genomic data unlocks unique and powerful therapeutic targets that would otherwise be missed.

Regeneron's Genetics Center is a key competitive advantage, functioning as a discovery engine for new drug targets. By sequencing millions of patient genomes and linking them to health records, it allows Regeneron to identify novel genetic variants associated with diseases, feeding its antibody development pipeline with proprietary targets.

To overcome the scaling challenges of traditional biobanks, Regeneron is pioneering a new model. They partner with companies specializing in aggregating de-identified health records and, separately, with groups handling bio-sampling. This "uncoupled" approach allows them to link massive, independent data streams to achieve unprecedented scale.

Instead of traditional methods, Regeneron sequences millions of people to find "superhumans"—those with rare genetic mutations that protect them from diseases. By studying these individuals, they identify high-confidence drug targets that mimic these natural protections, aiming for a higher probability of success in development.

While public AI models are powerful, they risk becoming commodities when trained on the same public data. Regeneron's strategy is to create a durable advantage by training AI models on its unique dataset of millions of genomes, proteomes, and linked health records to deeply understand human biology.

Regeneron systematically expands the market for its drugs through "indication expansion." By identifying people in its database with a natural loss-of-function variant for a drug's target, they can scan thousands of diseases to see what other conditions these people are protected from, revealing new therapeutic opportunities.

While the industry success rate for drugs entering the clinic is only about 10%, programs with human genetics backing have a 2-3x higher probability of approval. Regeneron reports its success rate is even higher, at four to five times the baseline, due to its strict focus on large-effect genetic signals.